This is about product-led thinking and strategic initiatives focused on long-term business health.. “You need an ecosystem of products, ours and other people's, to make this possible, but you first need leadership to give you permission to learn a direction, a strategy, the reasons you're doing this, and that, rarely, if ever, lives in one project.

These projects were significantly different in form, conception and function, but common threads in the design and delivery approach helped both to achieve success and industry recognition.. Pfizer API, Singapore: efficiency and value.This new API (active pharmaceutical ingredient) manufacturing plant is a flagship facility for Pfizer’s regional network, a $1bn SGD investment covering almost 430,000 square feet and delivered entirely during the COVID-19 pandemic.

The facility needed to represent best practice in GMP (good manufacturing practice) and digital automation while remaining cost effective to build and operate.. Bryden Wood was engaged to review and optimise a previously developed concept design for the site’s dry processing (milling and sieving) building.We worked closely with client stakeholders to analyse the root process requirements, identify over-provisions in the proposed design, and consolidate production onto less equipment.. Capturing these root requirements in 3D digital models called.“Chips” (sets of interacting components.

allowed us to rapidly evaluate a wide range of configuration options with client stakeholders engaged every step of the way..The reduced equipment requirements allowed us to pivot away from the originally proposed central spine corridor towards a simpler configuration of process rooms with perimeter circulation on both sides.

This, coupled with extensive deployment of glazing, allowed us to bring natural light to both circulation and process areas, enhancing the workplace environment and employee wellbeing.. Our alternative design for the milling building reduced operational CO. 2. emissions by more than 50% and capital cost by 30%.

It was adopted by Pfizer and incorporated into the delivered scheme.Consistent requirements across jurisdictions and customers could accelerate progress..

If the change to biogenic solvents can be made easier from a regulatory perspective, the next question is about the economics and supply Vs demand.If reducing usage and waste along with increased recycling can lead the way, then the unit cost of the solvent becomes less and less relevant..

Even now, the cost of solvent supply represents only 1% of Cost of Goods, although this amounts to $4bn globally.These numbers do not include the money spent by the industry to treat solvent waste, manage the safety risks, or pay any application of carbon tax..